Insilico Medicine, a Hong Kong-listed AI drug discovery company, said July 2 that it had signed a collaboration agreement with Takeda. The partnership aims to develop drug candidates in disease areas selected by Takeda through Insilico’s Pharma.AI platform.

Insilico said it will receive about US$60 million in upfront and near-term milestone payments.

It is also eligible for additional payments tied to preclinical, clinical, commercialization, and sales progress, bringing the deal’s total potential value to about US$600 million, plus tiered royalties.

Takeda will hold exclusive global rights to develop, manufacture, and commercialize any therapies arising from the collaboration.

Insilico completed its Hong Kong initial public offering in December 2025. The company said its platform has already entered clinical development. Among these  Rentosertib, an idopathic pulmonary fibrosis drug candidate that completed a Phase IIa trial in China.

The deal also aligns with Takeda’s broader research and development strategy.

🔗 Source: Security Times

Recent Insilico Medicine developments